UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/581,255	07/10/2006	Toshio Miyata	2006_0834A	1843
	7590 01/23/200 , LIND & PONACK, I	EXAMINER		
2033 K STREET N. W.			SZNAIDMAN, MARCOS L	
SUITE 800 WASHINGTON, DC 20006-1021			ART UNIT	PAPER NUMBER
			1611	
			MAIL DATE	DELIVERY MODE
			01/23/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/581,255	MIYATA ET AL.			
Office Action Summary	Examiner	Art Unit			
	MARCOS SZNAIDMAN	4173			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	lely filed the mailing date of this communication. (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on <u>30 No</u>	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) Claim(s) 1-26 is/are pending in the application.  4a) Of the above claim(s) 5,6,8,16-20, 23 and 2  5) Claim(s) is/are allowed.  6) Claim(s) 1-4,7,10-15, and 21-22 is/are rejected  7) Claim(s) 9 and 24 is/are objected to.  8) Claim(s) are subject to restriction and/or  Application Papers  9) The specification is objected to by the Examiner  10) The drawing(s) filed on is/are: a) access that application to the content of the content o	2 <u>5-26</u> is/are withdrawn from consi relection requirement. r. epted or b)  objected to by the E	Examiner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date 8.	4)  Interview Summary Paper No(s)/Mail Da 5)  Notice of Informal P 6)  Other:	ite			

### **DETAILED ACTION**

#### Election/Restrictions

Applicant's election of Group I (claims 1-15 and 21-24) and the following species: 1-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-6-methyl-1,3-dihydro-furo[3,4-c]pyridine-7-ol in the reply filed on November 30, 2007 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). Examination was expanded to the following species: 1-phenyl-3, 4-dimethyl-pyrazolin-5-one.

#### Status of Claims

Claims 1-26 are currently pending and are the subject of this office action.

Claims 5-6, 8, 16-20, 23 and 25-26 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected inventions/species, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on November 30, 2007.

Claims 1-4, 7, 9-15, 21-22 and 24 are presently under examination.

# **Priority**

The present application is a 371 of PCT/JP04/18038 filed on 12/03/2004, and claims priority to foreign application: JAPAN 2003-407834 filed on 12/05/2003.

# Claim Objections

Claims 9 and 24 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

# Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-4, 7, 10-15, and 21-22 are rejected under 35 U.S.C. 102(b) as being anticipated by Kleinpeter et. al. (Journal of Physical Organic Chemistry. 2001, 14:566-576).

Claims 1-4, 7, 10-15, and 21-22 recite a composition comprising 1-substitutedor unsubstituted, -3-substituted or unsubstituted, 2-pyrazolin-5-one.

For claims 1-4, 7, 10-15, and 21-22, Kleinpeter at. al. teach a compound with the following structure: 1-phenyl-3, 4-dimethyl-pyrazolin-5-one. The statements in claims 13-15: "a renal tissue protecting agent", "a peritoneal dialysate" and a "hemodialysis fluid" are considered intended use of the structure and not a claim limitation.

#### Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marcos L. Sznaidman whose telephone number is 571 270-3498. The examiner can normally be reached on Monday through Friday 9 AM to 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin H. Marschel can be reached on 571 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MLS January 8, 2007 Application/Control Number: 10/581,255 Page 5

Art Unit: 1614

/Ardin Marschel/ Supervisory Patent Examiner, Art Unit 1614

.